This site is intended for healthcare professionals
Industry news

Valeant Pharma to acquire Salix Pharma for $14.5 billion

Read time: 1 mins
Last updated:23rd Feb 2015
Published:23rd Feb 2015
Source: Pharmawand
Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Ltd. announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the Boards of Directors of both companies. Salix Pharmaceuticals is a widely recognized gastrointestinal market leader with a portfolio of 22 total products, including well-known prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a strong near- term pipeline of innovative, new assets.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.